Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96

Journal of Immunotherapy

Volumn 21, Issue 4, 1998, Pages 269-276

  Janetzki, Sylvia ^a,b   Blachere, Nathalie E ^a   Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antigens; Chaperones; Immunomodulators; Peptides

Indexed keywords

CANCER VACCINE; CHAPERONE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 96; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; CANCER CELL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; IMMUNOMODULATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, NEOPLASM; FEMALE; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED C3H; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0031869460     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199807000-00004     Document Type: Article

References (44)

1. Srivastava PK, Das MR. The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor-associated transplantation antigen. Int J Cancer 1984;33:417-22.
2. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986;83:3407-11.
3. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178:1391-6.
4. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994;152:5398-5403.
5. Ullrich SJ, Robinson EA, Law LW, Willingham W, Apella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci USA 1986;83:3121-5.
6. Feldweg AM, Srivastava PK. Molecular heterogeneity of tumor rejection antigen/heat shock protein gp96. Int J Cancer 1995;63: 310-14.
7. + T cells in vivo. Proc Natl Acad Sci USA 1994;91:3077-81.
8. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269:1585-8.
9. Li Z, Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J 1993;12:3143-51.
10. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994;39:93-8.
11. Srivastava PK, Old LJ. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 1988; 9:78-83.
12. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
13. Pardoll DM. Tumor antigens. A new look for the 1990s. Nature 1994;369:357.
14. Ramarathinam L, Sarma S, Marie M, et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol 1995;155:5323-9.
15. Ward PL, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989; 170:217-32.
16. + T-cell-dependent surveillance. Cancer Res 1990;50:3851-8.
17. Ozato K, Wan YJ, Orrison BM. Mouse major histocompatability class I gene expression begins at midsomite stage and is inducible in earlier-stage embryos by interferon. Proc Natl Acad Sci USA 1985;82:2427-31.
18. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984;312:548-51.
19. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocutes. Annu Rev Immunol 1989;7:601-24.
20. Pfeifer JD, Wick MJ, Roberts RL, et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-62.
21. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993;90:4942-6.
22. Kripke ML. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 1977;137:1395.
23. Schrek R. Qualitative and quantitative reactions of lymphocytes to x rays. Ann NY Acad Sci 1961;95:839-48.
24. Myers DK, DeWolfe DE, Araki K. Effects of x-radiation and of metabolic inhibitors on rat thymocytes in vitro. Can J Biochem Physiol 1962;40:1535-65.
25. Yamaguchi T. Relationship between survival period and dose of irradiation in rat thymocytes in vitro. Int J Radiat Biol 1967;12: 235-242.
26. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med 1990;171:801-17.
27. Mackay CR. T-cell memory: the connection between function, phenotype and migration pathways. Immunol Today 1991; 12: 189-92.
28. Michie CA, McLean A, Alcock C, Beverly PCL. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360:264-5.
29. Lowenthal JW, Harris AW. Activation of mouse lymphocytes inhibits induction of rapid cell death by x-irradiation. J Immunol 1995;135:1119-25.
30. Dunn PL, North RJ. Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J Leukocyte Biol 1991;49:388-96.
31. Sprent J. T and B memory cells. Cell 1994;76:315-22.
32. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177: 265-72.
33. Guilloux Y, Lucas S, Brichard VG, et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the /V-acetylglucosaminyltransferase V gene. J Exp Med 1996; 183:1173-83.
34. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1996;3:165-9.
35. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995; 1: 1297-1302.
36. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-82.
37. Mandelboim O, Vadai E, Fridkin M, et al. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nature Med 1995;1:1179-83.
38. Jaffee EM, Pardoll DM. Gene therapy: its potential applications in the treatment of renal-cell carcinoma. Semin Oncol 1995;22: 81-91.
39. Ebert EC, Roberts Al, O’Connell SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 1987;138:2161-8.
40. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-β-dependent but not the transforming growth factor-β-independent pathway of tumor cell mediated immunosuppression. J Immunol 1992;148:277-84.
41. + T cells. J Immunol 1992;149:949-56.
42. Rohrer JW, Coggin JM. CD8 T cell clones inhibit anti-tumor T cell function by secreting IL-10. J Immunol 1995; 5719-27.
43. Flynn GC, Pohl J, Flocco MT, Rothman JE. Peptide-binding specificity of the molecular chaperone BiP. Nature 19911353:726-30.
44. Blond-Elguindi S, Cwirla SE, Dower WJ, et al. Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 1993;75:717-28.